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Direct oral anticoagulants (DOACs) are a relatively recent addition to the oral anticoagulant armamentarium,
and provide an alternative to the use of vitamin K antagonists such as warfarin. Regardless of the type of agent
used, bleeding is the major complication of anticoagulant therapy. The decision to restart oral anticoagulation
following a major hemorrhage in a previously anticoagulated patient is supported largely by retrospective
studies rather than randomized clinical trials (mostly with vitamin K antagonists), and remains an issue of
individualized clinical assessment: the patient’s risk of thromboembolism must be balanced with the risk of
recurrent major bleeding. This review provides guidance for clinicians regarding if and when a patient should
be re-initiated on DOAC therapy following a major hemorrhage, based on the existing evidence.
 2016 Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).  The American Journal of Medicine (2016) 129, S54-S63
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America were estimated at 264 per 100,000 person-years
for men and 196 per 100,000 person-years for women in
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Elsevier Inc. This is an open access article under the CC BY
.1016/j.amjmed.2016.06.006dispensed in the United States during 2013.2 Yet OACs are
underused in many patients with AF, and an elevated risk of
stroke,3 contrary to the recommendations of multiple cur-
rent guidelines,4-6 with rates of OAC prescribing in
appropriately risk-stratiﬁed patients ranging from 40% to
60%.7,8 The most common complication of OAC therapy is
gastrointestinal (GI) bleeding, but the main cause of
bleeding-related morbidity and mortality is intracranial
hemorrhage (ICH).9-11 Physicians consistently underesti-
mate the risk of stroke in patients with AF and overestimate
the risk of hemorrhage with OAC therapy, leading to under-
treatment, despite evidence of the beneﬁts of OACs.8,12
This bias is exacerbated once a patient suffers a major
hemorrhage while receiving OAC therapy, particularly for
clinicians involved in the acute care of these episodes, as
the bleeding is apparent and dramatic, while the stroke that
may be prevented by OAC therapy is not. Although often
counterintuitive, restarting OACs after OAC-associated
major hemorrhage is usually appropriate; however, the
main issue concerns the timing of the restart. Evidence-
based data from prospective, randomized, controlled clin-
ical trials to address this question are needed, particularly in
direct oral anticoagulant (DOAC)-treated patients but are
unavailable at present.-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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bleeding episodes. Major hemorrhage is deﬁned by the
International Society on Thrombosis and Haemostasis as
fatal bleeding, or symptomatic bleeding in a critical area or
organ, or bleeding causing a fall in hemoglobin level of 20 g/L
(1.24 mmol/L or 2 g/dL) or more, or leading to transfusion of
2 units of whole blood or red cells.13 Consequently, patients
enrolled into studies of OAC-associated International Society
on Thrombosis and Haemostasis-deﬁned major bleeding
consist of a heterogeneous population arising from different
clinical specialties, which compounds the difﬁculties of
studying these scenarios. Estimates of the risk of major
hemorrhage related to OAC range from 2% to 3% in clinical
trials to approximately 1% to 7% in population cohort
studies.10,11,14 The exact incidence of major hemorrhage is
unknown because of uncertainty regarding the intensity of
OAC therapy, and patient-related factors such as history
of bleeding, concomitant disease, alcohol use, age, and risk of
falls.10 Regarding types ofmajor hemorrhage related to OAC,
the largest amount of published data is for ICH and GI
bleeding, and this reviewwill focus on these 2 clinical entities.
Recommendations for restarting OAC therapy in other major
bleeding situations, which are relatively rare, will remain as
riskebeneﬁt decisions for the individual clinician and patient.
For many decades, OAC therapy consisted of vitamin K
antagonists (VKAs), typically warfarin in the United States,
although other VKAs (eg, phenprocoumon and acenocou-
marol) are used in other geographical areas. VKAs act by
blocking vitamin K epoxide reductase to inhibit the acti-
vation of clotting factors (F) II, VII, IX, and X, and natural
anticoagulant proteins C and S. However, in recent years,
small-molecule DOACs have become available, the ﬁrst of
which was the direct thrombin inhibitor, dabigatran, which
gained U.S. Food and Drug Administration approval in
2010 for the risk reduction of stroke and systemic embolism
in patients with nonvalvular AF (NVAF). This was quickly
followed by the arrival of drugs that directly inhibit FXa
(apixaban, rivaroxaban, and edoxaban), which is 1 step
proximal to the action of direct FIIa inhibitors such as
dabigatran in the clotting cascade. Data from phase 3 clin-
ical trials in patients with NVAF demonstrated that these 4
DOACs were either noninferior or superior to warfarin in
terms of efﬁcacy (ie, reducing the rates of stroke and sys-
temic embolism),15-18 and showed equivalence or improved
safety (ie, major hemorrhage and clinically relevant
nonmajor hemorrhage) vs warfarin.15-18 DOACs were
associated with an approximately 30%-70% reduction in the
rates of ICH vs warfarin,15-18 although they were associated
with generally higher rates of GI bleeding (not further
deﬁned; annualized rate ranged from approximately 0.8% to
3.2% for DOACs [depending on the agent and dose] vs
approximately 1.0% to 2.2% for warfarin).15,16,18 DOACs
are also approved for the treatment and prevention of venous
thromboembolism (VTE), for which they were noninferior
to conventional therapy in terms of efﬁcacy outcomes, and
showed equivalence or improvement in the overall safety
proﬁle.19-22To date, comparatively few data have been published on
restarting OAC therapy after a major hemorrhage and the
data that do exist are almost exclusively from patients
receiving VKAs, with very few data concerning DOACs.
Furthermore, some expert opinion recommends approaching
the re-initiation of DOACs similarly to restart scenarios with
warfarin.23 This is reﬂected in the discussion below. This
review aims to summarize the key evidence and provide
guidance for clinicians regarding if and when a patient
should be restarted on DOAC therapy following a major
hemorrhage.INTRACRANIAL HEMORRHAGE AND
RE-INITIATION OF OACS
Intracranial hemorrhage has a heterogeneous etiology,
including spontaneous ICH (eg, lobar and deep hemispheric
hemorrhages, aneurismal subarachnoid hemorrhages, and
bleeding arteriovenous malformations) and traumatic ICH
(eg, extra-axial subdural, epidural hematomas, traumatic
subarachnoid hemorrhages, and intra-axial hemorrhagic
contusions). The risk of ICH recurrence can be related to
etiologic factors. For example, superﬁcial (lobar) hemor-
rhages are often caused by cerebral amyloid angiopathy, a
condition that affects cerebral arteries and arterioles and
increases the risk of hemorrhage, and is associated with
recurrence rates of up to 22%.24 The incidence of non-
traumatic ICH is approximately 25 per 100,000 person-
years.25 It has been estimated that there are approximately
67,000 cases of spontaneous ICH per year in the United
States,26 and anticoagulant-associated ICH accounts for
nearly 20% of those.26 The 30-day case fatality rate is as
high as 50%, and most survivors are left with some degree
of disability, which is often severe.26
In cases of OAC-related ICH, the therapeutic dilemma is
that stopping anticoagulation increases the risk of cerebral
ischemia, while continuing or restarting treatment after
stopping it increases the risk of recurrent bleeding.24 This
has been referred to as “steering between Scylla and
Charybdis,” meaning to have to choose between 2 evils.24
The published reports described below are all retrospective
analyses of OAC-related ICH, with varying patient pop-
ulations (eg, some studies focus on patients with NVAF or
patients with mechanical heart valves, while other studies
include patients treated for VTE). It should be noted that
DOACs are not approved for use in patients with mechan-
ical heart valves.
A recent report from a German multicenter, retrospective
study (2006-2012) assessed the effects of OAC resumption
in patients with anticoagulation-related (VKAs) spontaneous
ICH.27 Of the 1176 patients with data available, 719 patients
were part of the OAC resumption analysis (the remainder
were analyzed for hematoma enlargement [n ¼ 853] or long-
term outcomes [n ¼ 1083]). OAC was restarted in 172 of
719 (23.9%) patients (including 34/50 [68.0%] with me-
chanical heart valves, and 110/566 [19.4%] with AF).27
Median time to OAC resumption was 31 days
Figure Unmatched survival and event rates in atrial ﬁbrillation
patients: analyzing oral anticoagulant resumption status.
(Reproduced with permission from reference27) Unmatched
Kaplan-Meier survival curves, ischemic, and hemorrhagic event
rates in atrial ﬁbrillation (AF) patients with and without oral
anticoagulant (OAC) resumption. (A) Kaplan-Meier survival
rates of patients with AFwith and without OAC resumption from
index-intracranial hemorrhage (ICH) until 1-year follow-up,
analyzed by log-rank, Breslow, and TaroneeWare testing,
with corresponding P values. (B) Incidence rates of new
ischemic events over the 1-year follow-up period in patients with
and without OAC resumption. (C) Incidence rates of hemor-
rhagic events over the 1-year follow-up period in patients with
and without OAC resumption. Numbers for patients at risk
apply to parts AeC. One year after OAC-related ICH 8.2%
(n ¼ 9/110) of resumed patients vs 37.5% (n ¼ 171/456) of
patients without OAC resumption had died (P < .001). The
crude incidence of bleeding events was not signiﬁcantly different
among AF patients with and without OAC resumption (OAC
resumed: 7.3% [n ¼ 8/110] vs 5.7% [n ¼ 26/456] nonresumed
patients; P ¼ .532), the incidence of new ischemic events was
signiﬁcantly increased in patients without OAC resumption
(5.4% [n ¼ 6/110] vs 14.9% [n ¼ 68/456]; P ¼ .008).
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was associated with fewer ischemic events (OAC 9/172
[5.2%]; no OAC 82/547 [15.0%]; P < .001), and no
signiﬁcant increase in hemorrhagic complications (OAC14/172 [8.1%]; no OAC 36/547 [6.6%]; P ¼ .48) (Figure).27
Furthermore, there was a decrease in long-term mortality in
the subgroup of patients with AF who restarted OAC (pro-
pensity-matched survival analysis, hazard ratio [HR] 0.258;
95% conﬁdence interval [CI], 0.125-0.534; P < .001).27
Another study linked 3 large Danish registries (1997-
2013), and assessed the risk of recurrent stroke and
mortality when restarting OAC in patients with AF and
OAC-associated ICH (n ¼ 1752).28 The majority of patients
received VKA (65%) or VKA plus antiplatelet therapy
(33%), and a small proportion received DOACs (2%) or
DOACs plus antiplatelet therapy (<1%). The overall event
rates (using 1 year of follow-up) of the combined end point
of ischemic stroke/systemic embolism and all-cause mor-
tality (per 100 person-years) for patients treated with OAC
was 13.6 vs 27.3 for nontreated patients (HR 0.55; 95% CI,
0.39-0.78; no P-value stated).28 Of patients who resumed
OAC treatment after ICH (n ¼ 621), the overall median
time from ICH to the ﬁrst claimed prescription was 34
days.28
A Canadian registry study of 284 spontaneous warfarin-
related ICH (intracerebral or subarachnoid hemorrhage)
cases, in which warfarin was restarted in 91 (32%) patients,
reported that there was no increase in 30-day mortality
(adjusted odds ratio 0.49; 95% CI, 0.26-0.93; P ¼ .03) in pa-
tients who restarted warfarin.29 This trend continued at 1 year
but was no longer signiﬁcant (adjusted odds ratio 0.79; 95%
CI, 0.43-1.43;P¼ .43).29This study includedVTE indications
and valve prosthesis for OAC therapy, in addition to AF.
A retrospective, 3-center analysis of 234 patients with
warfarin-associated ICH found a 5-fold increased risk of
recurrent ICH with the resumption of OAC in the imme-
diate period (median time: 5.6 weeks; IQR 2.6-17) after the
index event (HR 5.6; 95% CI, 1.8-17.2; P ¼ .0029), and the
HR for ischemic stroke was 0.11 (95% CI, 0.014-0.87;
P ¼ .036).30 The combined risk of recurrent ICH and
ischemic stroke reached its lowest point if OAC therapy
was restarted between 10 and 30 weeks after the index
event.30
A further report, in which 7 clinical experts assessed
scenarios concerning acute reversal and resumption of OAC
in the setting of warfarin-associated ICH, revealed that
expert opinion favored OAC resumption within 3-10 days of
ICH if the patient was stable and anticoagulation was
mandatory.31 A shorter time to restarting OAC therapy, as
early as 72 hours post-bleed, was also recommended in a
review of 63 publications that described 492 patients with
warfarin-associated central nervous system hemorrhage
(including spinal hemorrhage).32
Lastly, a retrospective review (1976-1999) of 141
patients with ICH at high thromboembolic risk (OAC
indications: mechanical heart valve, AF, and prior stroke)
found that discontinuation of warfarin for 1-2 weeks
(median time not receiving warfarin 10 days; range 0-30
days) had a comparatively low probability of embolic
events, and there was no recurrence of ICH at 30 days for
the 35 patients who were restarted on OAC.33
Table 1 Major Guideline Recommendations on Re-Initiation of OAC Following a Major Bleed
Guideline and Citation Recommendation
European Stroke Organisation (ESO)
guidelines for the management of
spontaneous intracerebral hemorrhage, 201450
Recommendation 18: Unable to make ﬁrm recommendations about whether and when
to resume antithrombotic drugs after ICH in the absence of RCTs to address
treatment dilemmas
Additional information: Suggested timings for restarting these drugs range from not
earlier than 14 days up to 30 weeks (data from observational studies)30,31
Guidelines for the management of spontaneous
intracerebral hemorrhage (American Heart
Association/American Stroke Association), 201551
Prevention of Recurrent ICH, Recommendation 6: Optimal timing to resume OAC after
OAC-related ICH is uncertain. Avoidance of OAC for at least 4 weeks, in patients
without mechanical heart valves, might decrease the risk of ICH recurrence. If
indicated, aspirin monotherapy can probably be restarted in the days after ICH,
although the optimal timing is uncertain
Antithrombotic and thrombolytic therapy for
ischemic stroke, (Antithrombotic Therapy and
Prevention of Thrombosis, 9th ed: American
College of Chest Physicians), 201252
Recommendation 4.3: In patients with a history of a symptomatic primary ICH, we
suggest against the long-term use of antithrombotic therapy for the prevention of
ischemic stroke
Remarks: Patients with a history of ICH who might beneﬁt from antithrombotic therapy
are those at relatively low risk of recurrent ICH (eg, with deep hemorrhages) and
relatively high risk (>7% per year) of cardiac thromboembolic events (eg, with
mechanical heart valves or CHADS2* score of 4 points)
ICH ¼ intracranial hemorrhage; OAC ¼ oral anticoagulant; RCT ¼ randomized controlled trial.
*CHADS2, (score for atrial ﬁbrillation stroke risk) congestive heart failure history, hypertension history, age 75 years, diabetes mellitus history, stroke
or transient ischemic attack previously (see also Table 2).
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RE-INITIATION OF OACS
Gastrointestinal bleeding also has a diverse etiology
(eg, hemorrhagic gastritis, peptic ulcer disease, arteriove-
nous malformations, and diverticulosis), but has generally
been studied as a single cohort. Again, etiology plays a role
in recurrence risk, but it is difﬁcult to parse out. Acute GI
bleeds related to both VKA34 and DOAC18 therapy are more
common in the upper GI tract. Data from an open cohort
study (upper GI bleed n ¼ 21,641) gave an age-standardized
incidence rate (per 1000 person-years) for upper GI tract
bleeding of 5.8 in those prescribed warfarin and 2.7 in those
prescribed DOACs.34 A meta-analysis of data from 11 phase
3 randomized controlled trials reported no signiﬁcant dif-
ference in the overall incidence of major GI bleeding be-
tween DOACs and VKAs (relative risk 0.94; P ¼ .62).35
There is evidence, some of it prospective, that restarting
OAC therapy after GI hemorrhage is beneﬁcial.
A prospective observational study in the United States
identiﬁed 197 patients who developed GI bleeding while
receiving systemic anticoagulation (145/197 [74%] received
warfarin), of whom 76 (39%) discontinued anticoagulation
upon hospital discharge (ie, interruption of anticoagulation
for 72 hours after discharge).36 Restarting OAC therapy at
hospital discharge was associated with a lower risk of major
thrombotic episodes within 90 days (HR 0.121; 95% CI,
0.006-0.812; P ¼ .03), and no signiﬁcant difference in mor-
tality was observed (at 90 days, HR 0.632; 95% CI, 0.216-
1.89; P ¼ .40).36 Furthermore, restarting OAC was not
signiﬁcantly associated with an increased risk of recurrent GI
bleeding at 90 days (HR2.17; 95%CI, 0.861-6.67;P¼ .10).36
A retrospective United States cohort study enrolled pa-
tients with AF who developed GI bleeding while receivinganticoagulation (n ¼ 1329).37 Warfarin was restarted in 653
(49%) patients, after a median duration of 50 days (IQR 21-
78). Restarting warfarin was associated with reduced mor-
tality (adjusted HR 0.67; 95% CI, 0.56-0.81; P < .0001) and
decreased risk of thromboembolism (adjusted HR 0.71; 95%
CI, 0.54-0.93; P ¼ .01), but not recurrent GI bleeding
(adjusted HR 1.18; 95% CI, 0.94-1.10; P ¼ .47).37 When
the outcomes were stratiﬁed by duration of warfarin inter-
ruption, restarting warfarin after 7 days was not associated
with increased risk of GI bleeding, but was associated with
decreased risk of mortality and thromboembolism compared
with resuming after 30 days of interruption.37 These data are
in agreement with other studies.36,38 These ﬁndings were
extended in a recent meta-analysis that included this study
from the United States, and concluded that the resumption
of warfarin following interruption because of GI bleeding is
associated with a reduction in thromboembolic events and
mortality without a statistically signiﬁcant increase in
recurrent GI bleeding.39RISK STRATIFICATION AND CLINICAL
DECISION-MAKING
The overall annual risk of any major hemorrhage for
patients receiving OACs is 2% to 3%, with the annual risk
of OAC-related ICH at 0.3% to 0.5%.11 This must, however,
be considered against the annual risk of arterial thrombo-
embolism in the absence of OAC therapy, which is 12% to
22% for patients with mechanical heart valves, and 6% to
18% in patients with AF plus a CHA2DS2-VASc score of
3, and there is a 5% to 7% risk of VTE recurrence in the
ﬁrst 3 months for patients receiving OAC for previous
VTE.40-43 The clinical consequences of a thrombotic or
Table 2 Risk Stratiﬁcation Tools for Stroke Risk in Atrial Fibrillation57
Tool and Citation Risk Factor* Score
Tool Score
(if Stated)
Annual Event
Rate, %
(if Stated)
CHADS2
41 CHADS2 score Adjusted
stroke rate
CHF (recent) 1 0 1.9
Hypertension (history of) 1 1 2.8
Age 75 y 1 2 4.0
DM 1 3 5.9
Stroke/TIA 2 4 8.5
5 12.5
(6 ¼ max. score) 6 18.2
CHA2DS2-VASc
54 CHA2DS2-VASc
score
TEE rate
CHF/LV dysfunction 1 0 0
Hypertension 1 1 0.6
Age 75 y 2 2 1.6
DM 1 3 3.9
Stroke/TIA/TE 2 4 1.9
Vascular disease (prior MI, PAD, or aortic plaque) 1 5 3.2
Age 65-74 y 1 6 3.6
Sex category (female) 1 7 8.0
8 11.1
(9 ¼ max. score) 9 100
R2CHADS2
55
Renal dysfunction (CrCl <60 mL/min) 2
CHF (recent) 1
Hypertension 1
Age 75 y 1
DM 1
Stroke/TIA 2
(8 ¼ max. score)
QStroke (QResearch
database Stroke)56,57
Age (at entry) y Range, 25-84
Sex Separate models for
male and female
Treated hypertension (diagnosis of
hypertension and 1 current prescription
for 1 antihypertensive agent)
Yes/No
T1DM Yes/No
T2DM Yes/No
AF Yes/No
CHF Yes/No
CHD Yes/No
Self-assigned ethnicity (White/not recorded,
Indian, Pakistani, Bangladeshi, other Asian,
Black Caribbean, Black African,
Chinese, other/mixed)
9 categories
Townsend Deprivation Score Continuous
Smoking status (nonsmoker, ex-smoker,
light smoker [<10 cigarettes/day],
moderate smoker [10-19 cigarettes/day],
heavy smoker [20 cigarettes/day])
5 categories
SBP Continuous
TC:HDL-C ratio Continuous
BMI Continuous
Family history of coronary disease
(in ﬁrst-degree relative age <60 y)
Yes/No
RA Yes/No
CKD Yes/No
Valvular heart disease Yes/No
(99% ¼ max. score)
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Table 2 Continued
Tool and Citation Risk Factor* Score
Tool Score
(if Stated)
Annual Event
Rate, %
(if Stated)
ATRIA (Anticoagulation
and Risk Factors in
Atrial Fibrillation)
Stroke58
Prior stroke
Without With
Age, y
85 6 9
75-84 5 7
65-74 3 7
<65 0 8
Female sex 1 1
DM 1 1
CHF 1 1
Hypertension 1 1
Proteinuria 1 1
eGFR <45 mL/min/1.73 m2 or ESRD 1
(12 ¼ max.
score)
1
(15 ¼ max.
score)
AF ¼ atrial ﬁbrillation; BMI ¼ body mass index; CHD ¼ coronary heart disease; CHF ¼ congestive heart failure; CKD ¼ chronic kidney disease;
CrCl ¼ creatinine clearance; DM ¼ diabetes mellitus; eGFR ¼ estimated glomerular ﬁltration rate; ESRD ¼ end-stage renal disease; HDL-C ¼ high-density
lipoprotein cholesterol; LV ¼ left ventricular; MI ¼ myocardial infarction; PAD ¼ peripheral artery disease; RA ¼ rheumatoid arthritis; SBP ¼ systolic blood
pressure; T1 ¼ type 1 (DM); T2 ¼ type 2 (DM); TC ¼ total cholesterol; TE ¼ thromboembolism; TEE¼ thromboembolic event; TIA¼ transient ischemic attack.
*First letter of each row spells out the acronym, unless otherwise stated.
Table 3 Risk Stratiﬁcation Tools for Bleeding Risk in Atrial Fibrillation57
Tool and Citation Risk Factor* Score
HAS-BLED59 Hypertension (SBP >160 mm Hg) 1
Abnormal renal or liver function 1 or 2
Stroke 1
Bleeding history or predisposition 1
Labile INRs (if on warfarin) 1
Elderly (eg, age >65 y, frail condition) 1
Drugs (eg, concomitant antiplatelet or NSAIDs) or alcohol excess/abuse 1 or 2
(9 ¼ max. score)
HEMORR2HAGES
60 Hepatic or renal disease 1
Ethanol abuse 1
Malignancy 1
Older age (>75 y) 1
Reduced platelet count or function 1
Re-bleeding risk 2
Hypertension (uncontrolled) 1
Anemia 1
Genetic factors (CYP2C9 SNP) 1
Excessive fall risk 1
Stroke 1
(12 ¼ max. score)
ATRIA (Anticoagulation and
Risk Factors in Atrial
Fibrillation) bleeding61
Anemia 3
Severe renal disease (eGFR <30 mL/min/1.73 m2 or dialysis dependent) 3
Age 75 y 2
Prior hemorrhage 1
Diagnosed hypertension 1
(10 ¼ max. score)
CYP2C9 ¼ cytochrome P450 2C9; eGFR ¼ estimated glomerular ﬁltration rate; INR ¼ international normalized ratio; NSAIDs ¼ nonsteroidal anti-
inﬂammatory drugs; SBP ¼ systolic blood pressure; SNP ¼ single nucleotide polymorphism.
*First letter of each row spells out the acronym, unless otherwise stated.
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Table 4 Risk Stratiﬁcation Tools for Predicting Venous Thromboembolism Risk Recurrence65
Tool and Citation Risk Factor Score
HERDOO2 (Hyperpigmentation,
Edema, Redness, D-dimer,
Obesity, Older age, 2 scores)62
Clinical decision rule to identify patients at low
risk of recurrent VTE after 5-7 months
of OAC therapy
Men Always long-term AC
Women Long-term AC if score 2
Predictive factors for women Score
Post-thrombotic signs (hyperpigmentation, edema,
or redness in either leg)
1
D-dimer level 250 mg/L (during anticoagulation) 1
BMI 30 kg/m2 1
Age 65 years 1
Vienna (Medical University
of Vienna)63
Sex
Male 60
Female 0
Site of VTE
Distal DVT 0
Proximal DVT 70
Pulmonary embolism 90
D-dimer levels
Continuous
(Low risk of recurrence with score 180)
0-100
DASH (D-dimer level, young Age,
male Sex, and Hormonal therapy
associated with the index VTE event)64
Elevated D-dimer levels 1 month after stopping VKAs 2
Age <50 y 1
Male sex 1
Women taking oral contraceptives
(Low risk of recurrence with score 180)
2
AC ¼ anticoagulation; BMI ¼ body mass index; DVT ¼ deep vein thrombosis; OAC ¼ oral anticoagulant; VKA ¼ vitamin K antagonist; VTE ¼ venous
thromboembolism.
S60 The American Journal of Medicine, Vol 129, No 11A, November 2016bleeding event must also be taken into consideration when
deciding to restart OACs. For example, mechanical heart
valve thrombosis is fatal in approximately 12% of patients,
embolic stroke results in death in up to 27% of cases, while
VTE has a case-fatality rate of approximately 4% to 14%,
and major bleeding has a case-fatality rate of approximately
9% to 13%.44-49 Most of the major guidelines, including
those from the American Heart Association/American
Stroke Association, the American College of Chest Physi-
cians, and the European Stroke Organisation, provide advice
on whether to restart OAC therapy after major hemorrhage
in appropriately risk stratiﬁed patients, although they differ
over the timing (Table 1).30,31,50-52 For example, the
American Heart Association/American Stroke Association
guidelines for the management of spontaneous ICH had
previously advised restarting OAC at 1 week after ICH,53
but recently revised their guidance and now recommend
avoidance of OACs for at least 4 weeks in patients without
mechanical heart valves.51
Evaluation of an individual’s risk factors for stroke,
bleeding, and VTE recurrence is essential to understanding
the risks and beneﬁts of OAC therapy for that individual,
and several risk-stratiﬁcation tools are available
(Table 2,41,54-58 Table 3,57,59-61 and Table 462-65). TheCHA2DS2-VASc score
54 to assess stroke risk and the HAS-
BLED score59 to assess bleeding risk are the most
commonly used tools, as recommended by the current
guidelines.5,6 The HAS-BLED score was used to identify
modiﬁable risk factors for bleeding.5 It should be noted that
these schemes were developed in populations with AF and
did not include patients with VTE. The same is true of the
HEMORR2HAGES score for bleeding risk,
60 whereas the
Outpatient Bleeding Risk Index (OBRI) validation did
include patients with VTE.66 Validated scores for predicting
VTE recurrence include HERDOO2,62 the Vienna model,63
and DASH.64 Unfortunately, bleeding scores (OBRI,
HEMORR2HAGES, HAS-BLED, and ATRIA
61) have
shown poor discriminatory ability to predict major bleeding
and clinically relevant nonmajor bleeding in subsequent
external validation studies.67
A broad clinical assessment must be performed following
an OAC-related major hemorrhage, including identiﬁcation
of the underlying reason for which the patient originally
received anticoagulation therapy and their risk of stroke or
VTE and bleeding. Factors that would favor restarting
OAC therapy include the presence of deep ICH, a
mechanical heart valve, secondary prevention, or high risk of
stroke or VTE.68 A corrected cause of bleeding (eg, a clipped
Milling and Spyropoulos Anticoagulant Re-Initiation After Major Bleed S61aneurysm or a repaired aortoenteric ﬁstula) would also
facilitate OAC restart. Factors that would confer an
unfavorable beneﬁterisk proﬁle for restarting OAC
therapy include lobar ICH, multiple microbleeds on gradient-
recalled-echo-magnetic resonance imaging (correlating with
cerebral amyloid angiopathy and an increased risk of ICH
recurrence), and a low risk of stroke or VTE.68
If a patient is deemed appropriate to restart OAC therapy,
the clinician must decide when re-initiation should occur,
and how rapidly therapeutic anticoagulation is needed. The
decision pathway for re-initiation of OAC therapy must
recognize when the increasing risk of thromboembolism
outweighs the decreasing risk of recurrent hemorrhage. Thus,
restarting OAC might be considered earlier in patients with
mechanical heart valves or stabilized GI bleeds, later with
inpatients with ICH or a low risk of stroke/VTE, and prob-
ably disregarded in cases of lobar ICH or in the presence of
intracranial microbleeds. As evidenced from the studies
described, the recommendations vary widely (eg, from
3 days31 to 30 weeks30 for ICH), and are based on retro-
spective data rather than prospective data from randomized,
controlled clinical trials. A recent nonsystematic review of
antithrombotic treatment and ICH by Hofmeijer et al24
concluded that OAC therapy should be resumed after 1-2
weeks in patients with deep ICH and high risk of cerebral
ischemia (ie, patients with NVAF and a CHA2DS2-VASc
score of 4 or a mechanical heart valve), but restart should
be later (ie, after 4 weeks) in other patients. A further
consideration when re-initiating OAC therapy is the time to
onset of action, which is much faster for DOACs than for
warfarin (0.5-4 hours vs 36-72 hours, respectively).69
Lastly, it should also be noted that the risk of thrombo-
embolism is still high in the immediate period after a major
hemorrhage, and that rapid reversal of OAC, regardless of
the method, can be attended by thromboembolic events in
some patients. A post hoc analysis of thromboembolic
complications after warfarin reversal, examining data from
388 patients presenting with acute major hemorrhage or in
need of urgent surgical intervention, reported that the inci-
dence of thromboembolic events in the ﬁrst 45 days was
similar following VKA reversal with either 4-factor
prothrombin complex concentrate or plasma (approxi-
mately 7% for each agent).70CONCLUSIONS
In summary, the decision to restart OAC therapy in a patient
receiving chronic OAC who has suffered from a major bleed
is a highly individualized assessment. The risk of throm-
boembolism must be balanced with the risk of recurrent
major bleeding in that individual, while taking into account
the morbidity and case-fatality of a thrombotic/bleed
outcome, in addition to the optimal time frame of when to
restart OAC. It is also dependent upon the original indica-
tion for OAC, and the type of major bleed from which the
patient suffered. Many patients with OAC-associated ICHs
can restart OAC at some point between 1 and 30 weeks, butcareful risk stratiﬁcation must be performed. Most patients
with OAC-associated clinically stable GI hemorrhages can
restart OAC at 1 week post index bleed. Currently, there are
few data on how DOACs might change the riskebeneﬁt
analysis of when to restart therapy after a major bleed event,
particularly in ICH. However, the available data are reas-
suring in that practitioners would expect approximately 50%
fewer of these events vs VKA-treated patients, which has
major implications from a public health perspective. A
larger number of well-designed studies are needed in this
area for both VKA and, especially, for DOAC-treated
patient groups.
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